BET inhibitors have been shown to attenuate proliferation of ovarian cancer cells by various mechanisms: (1) inhibition of oncogenic pathways like FoxM1 and JAK/STAT, (2) resensitization of resistant cells to platinum agents and PARP inhibitors, (3) dysregulation of oxidative stress response and glycolysis, (4) disruption of homologous recombination (HR) capacity in BRCA wild-type cells and others [13,14,15]. This evidence concerns the gene FOXM1 and ovarian cancer.